SVRA - Savara Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.44
+0.11 (+1.50%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.33
Open7.31
Bid6.83 x 800
Ask9.73 x 800
Day's Range7.20 - 7.64
52 Week Range7.05 - 17.19
Volume176,995
Avg. Volume148,652
Market Cap261.358M
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-1.86
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.43
Trade prices are not sourced from all markets
  • GlobeNewswire29 days ago

    Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th

    AUSTIN, Texas, Nov. 16, 2018 -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that Rob Neville, Savara’s Chief Executive Officer, will participate.

  • GlobeNewswirelast month

    Savara Reports Third Quarter 2018 Financial Results and Provides Business Update

    Completed Enrollment in Two Clinical Studies of Molgradex: IMPALA, a Pivotal Phase 3 Study and OPTIMA, a Phase 2a StudyIMPALA Top Line Results Expected Q2 2019OPTIMA Interim.

  • GlobeNewswirelast month

    Savara to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 7, 2018

    AUSTIN, Texas, Nov. 01, 2018 -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its third quarter 2018 financial results on.

  • GlobeNewswirelast month

    Savara Completes Enrollment in Molgradex OPTIMA Clinical Study for the Treatment of NTM

    Savara remains on track to report interim results from the OPTIMA study in the fourth quarter of 2018, with top line results expected in the second quarter of 2019. Molgradex is also being investigated in a global pivotal Phase 3 clinical study, called IMPALA, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).

  • Simply Wall St.2 months ago

    A Look At The Intrinsic Value Of Savara Inc (NASDAQ:SVRA)

    Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Savara Inc (NASDAQ:SVRA) as an investment opportunity by estimating the company’s Read More...

  • GlobeNewswire2 months ago

    Savara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP

    Molgradex is also being investigated in an open-label, multicenter, safety extension study, called IMPALA-X, to determine the long-term safety and utilization of Molgradex in patients with aPAP. IMPALA-X offers patients the opportunity to continue treatment with Molgradex for up to three years after completion of the pivotal Phase 3 IMPALA study.

  • GlobeNewswire3 months ago

    Savara Provides Enrollment Update on Molgradex Impala and OPTIMA Clinical Studies and Reaffirms Guidance for Topline Data

    Savara Inc. (SVRA), an orphan lung disease company, today provided patient enrollment updates for its Molgradex pivotal Phase 3 clinical study, IMPALA, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), as well as its Molgradex Phase 2a clinical study, OPTIMA,  for the treatment of nontuberculous mycobacterial (NTM) lung infection, both of which were guided to complete enrollment by the end of Q3 2018. Patient enrollment in the IMPALA study is currently at 129 patients out of a total target of 135 patients, with sufficient patients in screening to complete enrollment within the coming weeks and topline data still anticipated in Q2 2019.

  • ACCESSWIRE4 months ago

    Savara, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Savara, Inc. (NASDAQ: SVRA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:30 PM Eastern Time. To listen ...

  • Philadelphia Angel Group Keiretsu Joins Orphan Lung Disease Company, Savara, as It Rings Nasdaq Opening Bell
    Newsfile5 months ago

    Philadelphia Angel Group Keiretsu Joins Orphan Lung Disease Company, Savara, as It Rings Nasdaq Opening Bell

    Howard Lubert, President of the Keiretsu Forum Mid-Atlantic, a global angel investor network, joined Rob Neville CEO of Savara on Monday, June 23, 2018, to ring the Opening Bell at Nasdaq MarketSite. Philadelphia, Pennsylvania--(Newsfile Corp. - July 26, 2018) - Howard Lubert, President of the Keiretsu Forum Mid-Atlantic, a global angel investor network, joined Rob Neville CEO of Savara, (Nasdaq: SVRA), an orphan lung disease company, as they rang the Opening Bell at the ...

  • Why Savara Inc. Is Soaring Today
    Motley Fool6 months ago

    Why Savara Inc. Is Soaring Today

    Traders cheer after the company receives positive analyst coverage. Here's what investors need to know.

  • Marketwired7 months ago

    Savara to Host First Quarter 2018 Financial Results and Business Update Conference Call on Wednesday, May 9, 2018

    AUSTIN, TX--(Marketwired - May 01, 2018) - Savara Inc. (SVRA), an orphan lung disease company, today announced it will release its first quarter 2018 financial results on Wednesday, May 9, 2018. Savara management will also host a conference call for investors beginning at 5:30 p.m. ET on Wednesday, May 9, 2018 to discuss its first quarter 2018 financial results and to provide a business update. Shareholders and other interested parties may access the conference call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from elsewhere outside the U.S. and requesting the Savara Inc. call.